73 Olaparib in patients with biallelic BRCA1/2 inactivation 51. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New Engl J Med 2018;379:2495-505. 52. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New Engl J Med 2017;377:523-33. 53. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019;381:317-27. 54. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-9. 55. Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. 56. Paul Roepman EdB, Stef van Lieshout, Lieke Schoenmaker, Mirjam C Boelens, Hendrikus J Dubbink, Willemina RR Geurts-Giele, Floris H Groenendijk, Manon MH Huibers, Mariëtte EG Kranendonk, Margaretha GM Roemer, Marloes Steehouwer, Wendy WJ de Leng, Alexander Hoischen, Bauke Ylstra, Kim Monkhorst, Jacobus JM van der Hoeven, Edwin Cuppen. Clinical validation of Whole Genome Sequencing for routine cancer diagnostics. medRxiv 2020. 57. Monkhorst K, Samsom K, Schipper L, et al. Validation of whole genome sequencing in routine clinical practice. Ann Oncol 2020;31:S784-S. 3
RkJQdWJsaXNoZXIy MTk4NDMw